D’Arcy v. Myriad Genetics: A Demand for the “Made” or “Non-Information” and Clear Subject Matter?
In October 2015, the High Court of Australia (HCA) handed down D’Arcy v. Myriad Genetics and overturned the Full Court of the Federal Court of Australia by holding that key product claims from Myriad Genetics’ BRCA1 gene patent did not constitute manners of manufacture. Two years earlier, the Suprem...
Saved in:
| Published in | IIC - International Review of Intellectual Property and Competition Law Vol. 47; no. 5; pp. 537 - 568 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.08.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In October 2015, the High Court of Australia (HCA) handed down
D’Arcy v. Myriad Genetics
and overturned the Full Court of the Federal Court of Australia by holding that key product claims from Myriad Genetics’ BRCA1 gene patent did not constitute manners of manufacture. Two years earlier, the Supreme Court of the United States (SCOTUS) had similarly ruled against certain product claims from Myriad Genetics’ BRCA1 and BRCA2 patents, finding that simply isolated genetic sequences are not patentable subject matter. From their results, one could easily make the mistake of seeing the two decisions as being identical and placing Australia and the US at odds with Europe. However, as this article highlights, Australian law is conceptually different from US law and, strictly speaking, the HCA did not rule that isolated genetic sequences can never constitute patentable subject matter. However, at the end of the day, it is arguable that the laws are very similar in effect. This article examines the HCA decision and compares and contrasts it to that of SCOTUS. |
|---|---|
| AbstractList | In October 2015, the High Court of Australia (HCA) handed down
D’Arcy v. Myriad Genetics
and overturned the Full Court of the Federal Court of Australia by holding that key product claims from Myriad Genetics’ BRCA1 gene patent did not constitute manners of manufacture. Two years earlier, the Supreme Court of the United States (SCOTUS) had similarly ruled against certain product claims from Myriad Genetics’ BRCA1 and BRCA2 patents, finding that simply isolated genetic sequences are not patentable subject matter. From their results, one could easily make the mistake of seeing the two decisions as being identical and placing Australia and the US at odds with Europe. However, as this article highlights, Australian law is conceptually different from US law and, strictly speaking, the HCA did not rule that isolated genetic sequences can never constitute patentable subject matter. However, at the end of the day, it is arguable that the laws are very similar in effect. This article examines the HCA decision and compares and contrasts it to that of SCOTUS. |
| Author | Lai, Jessica C. |
| Author_xml | – sequence: 1 givenname: Jessica C. surname: Lai fullname: Lai, Jessica C. email: jessica.lai@unilu.ch organization: Max Planck Institute of Innovation and Competition Law |
| BookMark | eNp9kM9OAjEQxhujiYg8gLe-QLF_t7teDAFFEtCDem66bVcXoWu6xYQbr2GiL8eTWMSTB-YymfnmN5n5zsCxb7wD4ILgPsFYXrYcM1IgTDKEeZ4hcQQ6lBQCYcrkMehgTHJU5EKcgl7bznGKgueSkw54G203n4Ng1vCjD2frUGsLx867WJv2Cg7gyC21t7BqAoyvDm43XzNt3XbzDVMnVfeNRxOf5KWOdeN3wm5-uHA6wMdVOXcmwpmO0YXrc3BS6UXren-5C55vb56Gd2j6MJ4MB1NkmCQRUcYkLTXJdM6yrNSyYEZKK3HuqJS5ZryyggtCqC60wM5mljIqyspqjgvDWRfI_V4TmrYNrlKmjr_nxaDrhSJY7WxTe9tUsk3tbFMikeQf-R7qpQ7rgwzdM22a9S8uqHmzCj49eAD6AY5lhC4 |
| CitedBy_id | crossref_primary_10_1007_s40319_024_01536_7 crossref_primary_10_1186_s12910_018_0271_8 |
| Cites_doi | 10.1097/GIM.0b013e3181d72661 10.1093/jnci/94.2.80 10.2307/3481172 10.1038/nrg3255 10.1017/CBO9780511522673 10.1515/9781400828692 10.26686/vuwlr.v39i1.5454 10.1038/nbt.2173 10.1038/ejhg.2011.76 10.4337/qmjip.2015.04.05 10.1097/GIM.0b013e3181fc50bc 10.1097/00001888-200212001-00009 10.1108/14691930810870328 10.1353/sor.2006.0001 10.22145/flr.34.3.4 10.4337/9781784716622.00014 10.1038/458407a 10.1038/nbt1009-903 |
| ContentType | Journal Article |
| Copyright | Max Planck Institute for Innovation and Competition, Munich 2016 |
| Copyright_xml | – notice: Max Planck Institute for Innovation and Competition, Munich 2016 |
| DBID | AAYXX CITATION |
| DOI | 10.1007/s40319-016-0486-5 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Law |
| EISSN | 2195-0237 |
| EndPage | 568 |
| ExternalDocumentID | 10_1007_s40319_016_0486_5 |
| GroupedDBID | 2-G AFELW ALMA_UNASSIGNED_HOLDINGS F5P J8Q KFD KGA KGS OCQCK TAF W2G AAYXX CITATION |
| ID | FETCH-LOGICAL-c371t-23372ba16a8366ba793c77d708e2778a34fd545112a9a50ed6d2325bfda409c43 |
| IEDL.DBID | AGYKE |
| ISSN | 0018-9855 |
| IngestDate | Tue Jul 01 02:18:49 EDT 2025 Thu Apr 24 23:00:24 EDT 2025 Fri Feb 21 02:37:15 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Patent-eligible subject matter Information-chemical dichotomy Myriad genetics Australia Gene patents US |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c371t-23372ba16a8366ba793c77d708e2778a34fd545112a9a50ed6d2325bfda409c43 |
| PageCount | 32 |
| ParticipantIDs | crossref_citationtrail_10_1007_s40319_016_0486_5 crossref_primary_10_1007_s40319_016_0486_5 springer_journals_10_1007_s40319_016_0486_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-08-01 |
| PublicationDateYYYYMMDD | 2016-08-01 |
| PublicationDate_xml | – month: 08 year: 2016 text: 2016-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg |
| PublicationTitle | IIC - International Review of Intellectual Property and Competition Law |
| PublicationTitleAbbrev | IIC |
| PublicationYear | 2016 |
| Publisher | Springer Berlin Heidelberg |
| Publisher_xml | – name: Springer Berlin Heidelberg |
| References | EisenbergRSWhy the gene patenting controversy persistsAcad Med200277121381138710.1097/00001888-200212001-00009 RicketsonSBusiness method patents—A matter of convenience?Intellect Prop Q2003297130 BenowitzSFrench challenge to BRCA1 patent underlies European discontentJ Natl Cancer Inst2002942808110.1093/jnci/94.2.80 Van OverwalleGPolicy levers tailoring patent law to biotechnology. Comparing U.S. and European approachesUC Irvine Law Rev201212435517 LaiJCGene-related inventions in Europe: Purpose- vs function-bound protectionQueen Mary J Intellect Prop20155444947310.4337/qmjip.2015.04.05 HuysIMatthijsGVan OverwalleGThe fate and future of patents on human genes and genetic diagnostic methodsNat Rev20121344144810.1038/nrg3255 LemleyMLife after bilskiStanford Law Rev201163613151347 JolyYOpen source aproaches in biotechnology: Utopia revisitedMaine Law Rev2007592385405 DentC‘Generally inconvenient’: The 1624 statute of monopolies as political compromiseMelb Univ Law Rev200933415453 NicolDImplications of DNA patenting: reviewing the evidenceJ Law, Inf Sci2011211736 MatthijsGThe European BRCA patent oppositions and appeals: Coloring inside the linesNature2013318704710 van ZeebroeckNPatents and academic research: A state of the artJ Intellect Capital20089224626310.1108/14691930810870328 Australian Law Reform Commission (ALRC) (2004) Genes and ingenuity report: gene patenting and human health. Commonwealth of Australia Godt C (2007) Eigentum an Information, Tubingen: Mohr Siebeck GoldERCarboneJMyriad genetics: In the eye of the policy stormGenet Med2010124S39S7010.1097/GIM.0b013e3181d72661 DreyfussRCEvansJPFrom Bilski back to Benson: preemption, inventing around, and the case of genetic diagnosticsStanford Law Rev201163413491376 PilaJInherent patentability in Anglo-Australian law: A historyAust Intellect Prop J200314111148 ShermanBD’Arcy v. Myriad Genetics Inc: Patenting genes in AustraliaSyd Law Rev201537135146 FrankelSLord cooke and patents: The scope of ‘invention'VUWLR200839183 Bodkin C (2004) Patent law in Australia, 2nd edn, Sydney: Thomas Reuters, chpt 5 BiagioliMPatent republic: representing inventions, constructing rights and authorsSoc Res200673411291172 EisenbergRSNoncompliance, nonenforcement, nonproblem? Rethinking the anticommons in biomedical researchHouston Law Rev200945410591099 RicketsonSRichardonMDavisonMIntellectual property: Cases2013ChatswoodMaterials and Commentary. LexisNexis Butterworths Australia685686 BermanHMDreyfussRCReflections on the science and law of structural biology, genomics, and drug developmentUCLA Law Review2006534871908 Boehm K (1967) The British patent system, vol. I: Administration. Cambridge University Press, Cambridge, pp 14–16 MonottiALThe scope of ‘manner of new manufacture’ under the Patents Act 1990 (CTH) after Grant v. Commissioner of PatentsFederal Law Rev200634461479 GaisserSThe phantom menace of gene patentsNature200945840740810.1038/458407a LaiJCGene-related patents in Australia and New Zealand: taking a step backAust Intellect Prop J2015254181197 MacLeod C (1988) Inventing the industrial revolution. The English patent system, 1660–1800. Cambridge University Press, Cambridge, p. 205 HawkinsNThe impact of human gene patents on genetic testing in the United KingdomGenet Med20111332034010.1097/GIM.0b013e3181fc50bc Rimmer M (2012–2013) The empire of cancer: Gene patents and cancer voices. J Law Inf Sci 22(2):18–55 CohenJELemleyMAPatent scope and innovation in the software industryCalif Law Rev200189115710.2307/3481172 SimmonsDPWickhamMEGene patents in Australia: Where do we standNat Biotechnol201230432332410.1038/nbt.2173 LaiJCMyriad genetics and the BRCA patents in Europe: The implications of the US supreme court decisionUC Irvine Law Rev2016510411075 Lai JC (2016b) The nebulous ‘invention’: From ‘idea and embodiment’ to ‘idea/embodiment and observable physical effects’? In: J.C. Lai, MD Antoinette (eds) Intellectual property and access to im/material goods, Cheltenham. Edward Elgar, UK (forthcoming) HubickiSShermanBKenyonATRichardsonMRicketsonSWe have never been modern: The High Court’s decision in National Research Development Corporation v. Commissioner of PatentsLandmarks in Australian intellectual property law2009New YorkCambridge University Press7396 Huys I, Van Overwalle G, Matthijs G (2011) Gene and genetic diagnostic method patent claims: A comparison under current European and US patent law. Eur J Human Genet 19:1104–1107 WatcherPThe nature of DNAUCLA Law Rev Discourse20136092102 PilaJThe common law invention in its original formIntellect Prop Q20013209224 Bessen J, Meurer MJ (2008) Patent failure: How judges, bureaucrats, and lawyers put innovators at risk. Princeton: Princeton Univeristy Press, New Jersey HuysIMatthijsGVan OverwalleGLegal uncertainty in the area of genetic diagnostic testingNat Biotechnol2009271090390910.1038/nbt1009-903 RimmerMThe alchemy of junk: Patent law and non-coding DNAUniv Ottawa Law Technol J200632539599 G Overwalle Van (486_CR05) 2012; 1 ER Gold (486_CR12) 2010; 12 JC Lai (486_CR21) 2016; 5 M Biagioli (486_CR4) 2006; 73 486_CR02 486_CR24 486_CR03 486_CR22 486_CR01 N Zeebroeck van (486_CR36) 2008; 9 M Lemley (486_CR23) 2011; 63 Y Joly (486_CR18) 2007; 59 I Huys (486_CR17) 2012; 13 RS Eisenberg (486_CR10) 2009; 45 P Watcher (486_CR37) 2013; 60 S Frankel (486_CR04) 2008; 39 B Sherman (486_CR34) 2015; 37 RC Dreyfuss (486_CR8) 2011; 63 486_CR16 D Nicol (486_CR27) 2011; 21 S Benowitz (486_CR2) 2002; 94 S Ricketson (486_CR31) 2013 J Pila (486_CR29) 2003; 14 S Ricketson (486_CR30) 2003; 2 486_CR5 RS Eisenberg (486_CR9) 2002; 77 S Gaisser (486_CR11) 2009; 458 486_CR33 S Hubicki (486_CR14) 2009 486_CR1 JE Cohen (486_CR6) 2001; 89 C Dent (486_CR7) 2009; 33 JC Lai (486_CR19) 2015; 25 M Rimmer (486_CR32) 2006; 3 JC Lai (486_CR20) 2015; 5 I Huys (486_CR15) 2009; 27 DP Simmons (486_CR35) 2012; 30 N Hawkins (486_CR13) 2011; 13 HM Berman (486_CR3) 2006; 53 AL Monotti (486_CR26) 2006; 34 J Pila (486_CR28) 2001; 3 G Matthijs (486_CR25) 2013; 31 |
| References_xml | – reference: BermanHMDreyfussRCReflections on the science and law of structural biology, genomics, and drug developmentUCLA Law Review2006534871908 – reference: PilaJThe common law invention in its original formIntellect Prop Q20013209224 – reference: Godt C (2007) Eigentum an Information, Tubingen: Mohr Siebeck – reference: LaiJCMyriad genetics and the BRCA patents in Europe: The implications of the US supreme court decisionUC Irvine Law Rev2016510411075 – reference: HuysIMatthijsGVan OverwalleGLegal uncertainty in the area of genetic diagnostic testingNat Biotechnol2009271090390910.1038/nbt1009-903 – reference: RicketsonSBusiness method patents—A matter of convenience?Intellect Prop Q2003297130 – reference: BiagioliMPatent republic: representing inventions, constructing rights and authorsSoc Res200673411291172 – reference: LaiJCGene-related inventions in Europe: Purpose- vs function-bound protectionQueen Mary J Intellect Prop20155444947310.4337/qmjip.2015.04.05 – reference: DentC‘Generally inconvenient’: The 1624 statute of monopolies as political compromiseMelb Univ Law Rev200933415453 – reference: Van OverwalleGPolicy levers tailoring patent law to biotechnology. Comparing U.S. and European approachesUC Irvine Law Rev201212435517 – reference: MonottiALThe scope of ‘manner of new manufacture’ under the Patents Act 1990 (CTH) after Grant v. Commissioner of PatentsFederal Law Rev200634461479 – reference: Boehm K (1967) The British patent system, vol. I: Administration. Cambridge University Press, Cambridge, pp 14–16 – reference: LemleyMLife after bilskiStanford Law Rev201163613151347 – reference: WatcherPThe nature of DNAUCLA Law Rev Discourse20136092102 – reference: JolyYOpen source aproaches in biotechnology: Utopia revisitedMaine Law Rev2007592385405 – reference: FrankelSLord cooke and patents: The scope of ‘invention'VUWLR200839183 – reference: CohenJELemleyMAPatent scope and innovation in the software industryCalif Law Rev200189115710.2307/3481172 – reference: RicketsonSRichardonMDavisonMIntellectual property: Cases2013ChatswoodMaterials and Commentary. LexisNexis Butterworths Australia685686 – reference: Bodkin C (2004) Patent law in Australia, 2nd edn, Sydney: Thomas Reuters, chpt 5 – reference: NicolDImplications of DNA patenting: reviewing the evidenceJ Law, Inf Sci2011211736 – reference: HuysIMatthijsGVan OverwalleGThe fate and future of patents on human genes and genetic diagnostic methodsNat Rev20121344144810.1038/nrg3255 – reference: HawkinsNThe impact of human gene patents on genetic testing in the United KingdomGenet Med20111332034010.1097/GIM.0b013e3181fc50bc – reference: Huys I, Van Overwalle G, Matthijs G (2011) Gene and genetic diagnostic method patent claims: A comparison under current European and US patent law. Eur J Human Genet 19:1104–1107 – reference: Lai JC (2016b) The nebulous ‘invention’: From ‘idea and embodiment’ to ‘idea/embodiment and observable physical effects’? In: J.C. Lai, MD Antoinette (eds) Intellectual property and access to im/material goods, Cheltenham. Edward Elgar, UK (forthcoming) – reference: PilaJInherent patentability in Anglo-Australian law: A historyAust Intellect Prop J200314111148 – reference: BenowitzSFrench challenge to BRCA1 patent underlies European discontentJ Natl Cancer Inst2002942808110.1093/jnci/94.2.80 – reference: RimmerMThe alchemy of junk: Patent law and non-coding DNAUniv Ottawa Law Technol J200632539599 – reference: Rimmer M (2012–2013) The empire of cancer: Gene patents and cancer voices. J Law Inf Sci 22(2):18–55 – reference: Bessen J, Meurer MJ (2008) Patent failure: How judges, bureaucrats, and lawyers put innovators at risk. Princeton: Princeton Univeristy Press, New Jersey – reference: Australian Law Reform Commission (ALRC) (2004) Genes and ingenuity report: gene patenting and human health. Commonwealth of Australia – reference: GoldERCarboneJMyriad genetics: In the eye of the policy stormGenet Med2010124S39S7010.1097/GIM.0b013e3181d72661 – reference: van ZeebroeckNPatents and academic research: A state of the artJ Intellect Capital20089224626310.1108/14691930810870328 – reference: SimmonsDPWickhamMEGene patents in Australia: Where do we standNat Biotechnol201230432332410.1038/nbt.2173 – reference: EisenbergRSNoncompliance, nonenforcement, nonproblem? Rethinking the anticommons in biomedical researchHouston Law Rev200945410591099 – reference: GaisserSThe phantom menace of gene patentsNature200945840740810.1038/458407a – reference: DreyfussRCEvansJPFrom Bilski back to Benson: preemption, inventing around, and the case of genetic diagnosticsStanford Law Rev201163413491376 – reference: HubickiSShermanBKenyonATRichardsonMRicketsonSWe have never been modern: The High Court’s decision in National Research Development Corporation v. Commissioner of PatentsLandmarks in Australian intellectual property law2009New YorkCambridge University Press7396 – reference: MatthijsGThe European BRCA patent oppositions and appeals: Coloring inside the linesNature2013318704710 – reference: ShermanBD’Arcy v. Myriad Genetics Inc: Patenting genes in AustraliaSyd Law Rev201537135146 – reference: EisenbergRSWhy the gene patenting controversy persistsAcad Med200277121381138710.1097/00001888-200212001-00009 – reference: LaiJCGene-related patents in Australia and New Zealand: taking a step backAust Intellect Prop J2015254181197 – reference: MacLeod C (1988) Inventing the industrial revolution. The English patent system, 1660–1800. Cambridge University Press, Cambridge, p. 205 – volume: 3 start-page: 209 year: 2001 ident: 486_CR28 publication-title: Intellect Prop Q – volume: 63 start-page: 1349 issue: 4 year: 2011 ident: 486_CR8 publication-title: Stanford Law Rev – volume: 12 start-page: S39 issue: 4 year: 2010 ident: 486_CR12 publication-title: Genet Med doi: 10.1097/GIM.0b013e3181d72661 – volume: 94 start-page: 80 issue: 2 year: 2002 ident: 486_CR2 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/94.2.80 – volume: 89 start-page: 1 issue: 1 year: 2001 ident: 486_CR6 publication-title: Calif Law Rev doi: 10.2307/3481172 – volume: 13 start-page: 441 year: 2012 ident: 486_CR17 publication-title: Nat Rev doi: 10.1038/nrg3255 – volume: 31 start-page: 704 issue: 8 year: 2013 ident: 486_CR25 publication-title: Nature – ident: 486_CR24 doi: 10.1017/CBO9780511522673 – ident: 486_CR01 doi: 10.1515/9781400828692 – volume: 45 start-page: 1059 issue: 4 year: 2009 ident: 486_CR10 publication-title: Houston Law Rev – volume: 39 start-page: 83 issue: 1 year: 2008 ident: 486_CR04 publication-title: VUWLR doi: 10.26686/vuwlr.v39i1.5454 – volume: 30 start-page: 323 issue: 4 year: 2012 ident: 486_CR35 publication-title: Nat Biotechnol doi: 10.1038/nbt.2173 – volume: 63 start-page: 1315 issue: 6 year: 2011 ident: 486_CR23 publication-title: Stanford Law Rev – volume: 14 start-page: 111 year: 2003 ident: 486_CR29 publication-title: Aust Intellect Prop J – ident: 486_CR33 – ident: 486_CR16 doi: 10.1038/ejhg.2011.76 – ident: 486_CR5 – ident: 486_CR03 – volume: 5 start-page: 449 issue: 4 year: 2015 ident: 486_CR20 publication-title: Queen Mary J Intellect Prop doi: 10.4337/qmjip.2015.04.05 – volume: 13 start-page: 320 year: 2011 ident: 486_CR13 publication-title: Genet Med doi: 10.1097/GIM.0b013e3181fc50bc – volume: 33 start-page: 415 year: 2009 ident: 486_CR7 publication-title: Melb Univ Law Rev – volume: 5 start-page: 1041 year: 2016 ident: 486_CR21 publication-title: UC Irvine Law Rev – volume: 1 start-page: 435 issue: 2 year: 2012 ident: 486_CR05 publication-title: UC Irvine Law Rev – volume: 77 start-page: 1381 issue: 12 year: 2002 ident: 486_CR9 publication-title: Acad Med doi: 10.1097/00001888-200212001-00009 – volume: 59 start-page: 385 issue: 2 year: 2007 ident: 486_CR18 publication-title: Maine Law Rev – start-page: 73 volume-title: Landmarks in Australian intellectual property law year: 2009 ident: 486_CR14 – volume: 2 start-page: 97 year: 2003 ident: 486_CR30 publication-title: Intellect Prop Q – start-page: 685 volume-title: Intellectual property: Cases year: 2013 ident: 486_CR31 – ident: 486_CR1 – volume: 60 start-page: 92 year: 2013 ident: 486_CR37 publication-title: UCLA Law Rev Discourse – volume: 21 start-page: 7 issue: 1 year: 2011 ident: 486_CR27 publication-title: J Law, Inf Sci – volume: 3 start-page: 539 issue: 2 year: 2006 ident: 486_CR32 publication-title: Univ Ottawa Law Technol J – volume: 9 start-page: 246 issue: 2 year: 2008 ident: 486_CR36 publication-title: J Intellect Capital doi: 10.1108/14691930810870328 – volume: 53 start-page: 871 issue: 4 year: 2006 ident: 486_CR3 publication-title: UCLA Law Review – volume: 73 start-page: 1129 issue: 4 year: 2006 ident: 486_CR4 publication-title: Soc Res doi: 10.1353/sor.2006.0001 – ident: 486_CR02 – volume: 34 start-page: 461 year: 2006 ident: 486_CR26 publication-title: Federal Law Rev doi: 10.22145/flr.34.3.4 – volume: 37 start-page: 135 year: 2015 ident: 486_CR34 publication-title: Syd Law Rev – ident: 486_CR22 doi: 10.4337/9781784716622.00014 – volume: 458 start-page: 407 year: 2009 ident: 486_CR11 publication-title: Nature doi: 10.1038/458407a – volume: 27 start-page: 903 issue: 10 year: 2009 ident: 486_CR15 publication-title: Nat Biotechnol doi: 10.1038/nbt1009-903 – volume: 25 start-page: 181 issue: 4 year: 2015 ident: 486_CR19 publication-title: Aust Intellect Prop J |
| SSID | ssj0000948741 ssj0041851 |
| Score | 2.025062 |
| Snippet | In October 2015, the High Court of Australia (HCA) handed down
D’Arcy v. Myriad Genetics
and overturned the Full Court of the Federal Court of Australia by... |
| SourceID | crossref springer |
| SourceType | Enrichment Source Index Database Publisher |
| StartPage | 537 |
| SubjectTerms | Intellectual Property IT Law Law Law and Criminology Media Law |
| Title | D’Arcy v. Myriad Genetics: A Demand for the “Made” or “Non-Information” and Clear Subject Matter? |
| URI | https://link.springer.com/article/10.1007/s40319-016-0486-5 |
| Volume | 47 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV25TsQwEB2xS0PDjbjlggqUVeIjTmjQilPAUoGAKprYTrMQECwgqPY3kODn9kuwcywCARJlkkkUe8b2G3vmDcAaj32kSsYeSlfCDKn20GjlGcOy1BpQIAvi-c5JeHDGDy_ERZXHfV9Hu9dHksVMPUx242XCTWA9YB6FnmjAqIUfPm_CaHv_8uhza8V6LFFRUKackB09S1k4L7BjOxKiPtz86aNfl6evZ6PFkrM3Aaf1z5aRJt3WQy9tqZdvPI7_bM0kjFcQlLRLm5mCEZNPQ-MYn2aguzPov7bv1DN5bJHOszVOTRwxteNy3iRtsmOuMdfEAl1igSMZ9N86qM2g_07sHXt1cpN7VYKTU7h74OS3XW0KYucot-lDOgWl59YsnO3tnm4feFU5Bk8xGfQ8ypikKQYhRiwMU7QjW0mppR8ZKmWEjGdaOLozijEK3-hQW7gm0kyjdSIVZ3PQzG9yMw-EhX6WMcNRcbQIhscKtUIqKYsFihAXwK-1kKiKq9yVzLhKhizLRf8lLj7N9V8iFmB9-MptSdTxl_BGrZWkGrP3v0sv_kt6CcZooVYXJLgMzd7dg1mxwKWXrlaGugqNc3b8AU0x5BI |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9tAEF4VcigX6AsVKO0eemrlyN6H1-ZSWaQ0beKcgkRP1nh3fQk1CBJQOOVvILV_Lr-EWT9SpWorcbQ9trw7M7szOzPfEPJexD4wrWIPlGthBsx4YI32rOVFjgIUqAp4Ph2F_VPx7UyeNXXc1222exuSrFbqVbGbqAtuAvSARRR6coN0BLrgKNad5Mv3we-jFfRYoqqhTL0gO3iWunFegLodSdkGN__20fXtaT02Wm05Jztk3P5snWky6c6meVff_YHj-MjRPCPbjQlKk1pmnpMntnxBNoZw-5JMesvFfXKl5_SmS9M5CqehDpjaYTkf0YT27A8oDUVDl6LhSJeLnykYu1z8ongHr0YXpdcUODmGuweO_tj1pqC4RrlDH5pWkJ6fXpHTk8_j477XtGPwNFfB1GOcK5ZDEELEwzAH1GytlFF-ZJlSEXBRGOngzhjEIH1rQoPmmswLA-hEasF3yWZ5UdrXhPLQLwpuBWgBaMGIWIPRwBTjsQQZwh7xWy5kusEqdy0zzrMVynI1f5nLT3Pzl8k98mH1ymUN1PE_4o8tV7JGZ6__Tb3_KOp35Gl_nA6z4dfR4IBssYrFLmHwDdmcXs3sIRox0_xtI7QPytfmCg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB7BIlVcWvoStEB96IkqS-JHnPSCVizLc1c9FAlO6cR2LtuG1RJa0dP-DST4c_tLsPNYBIJKFcckkyj2zNhje-b7AD7z2EeqZOyhdBRmSLWHRivPGJal1oACWQLP9wfh3jE_OBEnNc_peZPt3hxJVjUNDqUpLzZHOtucFb7xqvgmsKthHoWemIcF7qDtWrDQ2T09vNtmsauXqCSXqQZnB9VSkegF1s8jIZqDzsc-en-qun9OWk4_vVfwo_nxKutk2L4o0rb6-wDT8RktW4KXdWhKOpUtvYY5k7-B-SP88xaG3enkqjNWl-R3m_QvrdFq4gCrHcbzV9IhXfMLc01sAExsQEmmk-s-ajOd3BB7x14NznKvLnxyhuAeOPltx1lB7NjlNoNIv4T63HoHx72d79t7Xk3T4Ckmg8KjjEmaYhBixMIwRevxSkot_chQKSNkPNPCwaBRjFH4RofahnEizTTaxaXi7D208rPcLANhoZ9lzHBUHG1kw2OFWiGVlMUCRYgr4DcaSVSNYe6oNH4mM_Tlsv8Sl7fm-i8RK7Axe2VUAXj8S_hLo6Gk9uXzp6U__Jf0J3jxrdtLjvYHhx9hkZYadnmEq9AqxhdmzcY2Rbpe2-8toO7u7g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=D%E2%80%99Arcy+v.+Myriad+Genetics%3A+A+Demand+for+the+%E2%80%9CMade%E2%80%9D+or+%E2%80%9CNon-Information%E2%80%9D+and+Clear+Subject+Matter%3F&rft.jtitle=IIC+-+International+Review+of+Intellectual+Property+and+Competition+Law&rft.au=Lai%2C+Jessica+C.&rft.date=2016-08-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0018-9855&rft.eissn=2195-0237&rft.volume=47&rft.issue=5&rft.spage=537&rft.epage=568&rft_id=info:doi/10.1007%2Fs40319-016-0486-5&rft.externalDocID=10_1007_s40319_016_0486_5 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0018-9855&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0018-9855&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0018-9855&client=summon |